These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 27432383

  • 21. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
    Okubo H, Akiyama J, Kobayakawa M, Kawazoe M, Mishima S, Takasaki Y, Nagata N, Shimada T, Yokoi C, Komori S, Kimura K, Hisada Y, Iwata E, Watanabe K, Yanagisawa N, Shiroma S, Shimomura A, Okahara K, Cho H, Uemura N.
    J Gastroenterol; 2020 Nov; 55(11):1054-1061. PubMed ID: 32930864
    [Abstract] [Full Text] [Related]

  • 22. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication.
    Sue S, Kuwashima H, Iwata Y, Oka H, Arima I, Fukuchi T, Sanga K, Inokuchi Y, Ishii Y, Kanno M, Terada M, Amano H, Naito M, Iwase S, Okazaki H, Komatsu K, Kokawa A, Kawana I, Morimoto M, Saito T, Kunishi Y, Ikeda A, Takahashi D, Miwa H, Sasaki T, Tamura T, Kondo M, Shibata W, Maeda S.
    Intern Med; 2017 Nov; 56(11):1277-1285. PubMed ID: 28566587
    [Abstract] [Full Text] [Related]

  • 23. A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori.
    Noda H, Noguchi S, Yoshimine T, Goji S, Adachi K, Tamura Y, Izawa S, Ebi M, Yamamoto S, Ogasawara N, Funaki Y, Sasaki M, Kasugai K.
    J Gastrointestin Liver Dis; 2016 Sep; 25(3):283-8. PubMed ID: 27689190
    [Abstract] [Full Text] [Related]

  • 24. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication.
    Kusunoki M, Yuki M, Ishitobi H, Kobayashi Y, Nagaoka M, Takahashi Y, Fukuba N, Komazawa Y, Shizuku T, Kinoshita Y.
    Intern Med; 2019 Jun 01; 58(11):1549-1555. PubMed ID: 30713328
    [Abstract] [Full Text] [Related]

  • 25. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
    Jung YS, Kim EH, Park CH.
    Aliment Pharmacol Ther; 2017 Jul 01; 46(2):106-114. PubMed ID: 28497487
    [Abstract] [Full Text] [Related]

  • 26. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan.
    Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, Nakahara M, Kawabe K.
    Gut; 2020 Jun 01; 69(6):1019-1026. PubMed ID: 31915235
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetic Interactions Between Tegoprazan and the Combination of Clarithromycin, Amoxicillin and Bismuth in Healthy Chinese Subjects: An Open-Label, Single-Center, Multiple-Dosage, Self-Controlled, Phase I Trial.
    Du Y, Yu L, Deng B, Li Q, Hu J, Li L, Xu Y, Song L, Xie F, Wang Y, Chen Y, Liu C, Zhai X, Lu Y.
    Clin Drug Investig; 2024 May 01; 44(5):343-355. PubMed ID: 38615091
    [Abstract] [Full Text] [Related]

  • 28. Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan.
    Horie R, Handa O, Ando T, Ose T, Murakami T, Suzuki N, Sendo R, Imamoto E, Itoh Y.
    Helicobacter; 2020 Aug 01; 25(4):e12698. PubMed ID: 32368846
    [Abstract] [Full Text] [Related]

  • 29. Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: Systematic review and meta-analyses of randomized controlled trials.
    Liu L, Shi H, Shi Y, Wang A, Guo N, Li F, Nahata MC.
    Helicobacter; 2024 Aug 01; 29(3):e13094. PubMed ID: 38790090
    [Abstract] [Full Text] [Related]

  • 30. Therapeutic efficacy and drug safety comparison of one-week Vonoprazan triple therapy with two-weeks Esomeprazole triple therapy in Helicobacter pylori infection: Findings from a single-centre randomized clinical trial in population of Pakistan.
    Waqar F, Noor M, Haider E, Farhat K, Ali S, Fatime Gilani SF.
    J Pak Med Assoc; 2024 Mar 01; 74(3):432-435. PubMed ID: 38591272
    [Abstract] [Full Text] [Related]

  • 31. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.
    Matsumoto H, Shiotani A, Katsumata R, Fujita M, Nakato R, Murao T, Ishii M, Kamada T, Haruma K, Graham DY.
    Dig Dis Sci; 2016 Nov 01; 61(11):3215-3220. PubMed ID: 27659671
    [Abstract] [Full Text] [Related]

  • 32. Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment.
    Puig I, Baylina M, Sánchez-Delgado J, López-Gongora S, Suarez D, García-Iglesias P, Muñoz N, Gisbert JP, Dacoll C, Cohen H, Calvet X.
    J Antimicrob Chemother; 2016 Oct 01; 71(10):2740-53. PubMed ID: 27342548
    [Abstract] [Full Text] [Related]

  • 33. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori.
    Bunchorntavakul C, Buranathawornsom A.
    J Gastroenterol Hepatol; 2021 Dec 01; 36(12):3308-3313. PubMed ID: 34622504
    [Abstract] [Full Text] [Related]

  • 34. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin.
    Ono S, Kato M, Nakagawa S, Mabe K, Sakamoto N.
    Helicobacter; 2017 Jun 01; 22(3):. PubMed ID: 28098408
    [Abstract] [Full Text] [Related]

  • 35. The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
    Echizen H.
    Clin Pharmacokinet; 2016 Apr 01; 55(4):409-18. PubMed ID: 26369775
    [Abstract] [Full Text] [Related]

  • 36. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
    Kajihara Y, Shimoyama T, Mizuki I.
    Scand J Gastroenterol; 2017 Feb 01; 52(2):238-241. PubMed ID: 27806639
    [Abstract] [Full Text] [Related]

  • 37. Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China.
    Gao W, Teng G, Wang C, Xu Y, Li Y, Cheng H.
    Helicobacter; 2022 Oct 01; 27(5):e12918. PubMed ID: 35877765
    [Abstract] [Full Text] [Related]

  • 38. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
    Uygun A, Kadayifci A, Yesilova Z, Safali M, Ilgan S, Karaeren N.
    Clin Ther; 2008 Mar 01; 30(3):528-34. PubMed ID: 18405790
    [Abstract] [Full Text] [Related]

  • 39. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
    Furuta T, Yamade M, Kagami T, Uotani T, Suzuki T, Higuchi T, Tani S, Hamaya Y, Iwaizumi M, Miyajima H, Umemura K, Osawa S, Sugimoto K.
    Digestion; 2020 Mar 01; 101(6):743-751. PubMed ID: 31434101
    [Abstract] [Full Text] [Related]

  • 40. Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.
    Kusano C, Gotoda T, Suzuki S, Ikehara H, Moriyama M.
    J Gastroenterol; 2018 Jun 01; 53(6):718-724. PubMed ID: 29110085
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.